We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMYRK RNS Number : 7656P York Pharma plc 31 March 2009 31 March 2009 York Pharma Plc (the "Company") Suspension of trading of securities on AIM On 20 March 2009, the Board of the Company announced that it was in discussions with two potential offerors and that these discussions included the provision of the necessary short term funding facilities to allow the Company to continue trading through the period needed to complete any formal offer for the Company under the Takeover Code. It was also announced on 20 March 2009 that the publication of the Company's results for the financial year ended 30 September 2008 (the "Results") would only take place after the Company had secured its short term funding needs. Discussions with the parties continue. However, as such short term funding is not yet available, the Company will now not be able, as required by the AIM Rules, to publish its Results prior to 31 March 2009. Accordingly, in accordance with the AIM Rules, all the Ordinary Shares and Warrants have been temporarily suspended today from trading on AIM, pending the publication of the Company's Results. The Board will provide a further update as and when appropriate. For more information please contact: +--------------------------------------+--------------------------------------+ | York Pharma Plc | Tel: +44 (0) 1908 764 020 | | Richard Anderson, Chief Executive | | | Officer | | | Ian Miscampbell, Chief Financial | | | Officer | | +--------------------------------------+--------------------------------------+ | | | +--------------------------------------+--------------------------------------+ | Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 | | Hugh Field / Adam Cowen | | +--------------------------------------+--------------------------------------+ | | | +--------------------------------------+--------------------------------------+ | Financial Dynamics | Tel: +44 (0) 207 831 3113 | | Ben Brewerton / Emma Thompson | | +--------------------------------------+--------------------------------------+ Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the United Kingdom by The Financial Services Authority is acting for the Company in relation to the matters described in this announcement and is not advising any other person, and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to customers of Collins Stewart or for providing advice in relation to the matters described in this announcement. About York Pharma (YRK.L) York Pharma is a pharmaceutical group, established in 2003, which develops, markets and supplies branded dermatological products to pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology. This information is provided by RNS The company news service from the London Stock Exchange END SRSDGGFFMGMGLZZ
1 Year York Pharma Chart |
1 Month York Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions